Evofem Biosciences Files 8-K for Material Agreement
Ticker: EVFM · Form: 8-K · Filed: May 8, 2025 · CIK: 1618835
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: EVFM
TL;DR
EVFM filed an 8-K on May 3rd for a material agreement - check for details.
AI Summary
Evofem Biosciences, Inc. filed an 8-K on May 8, 2025, reporting an entry into a material definitive agreement and financial statements. The filing date indicates the report was made public on May 8, 2025, with the earliest event reported on May 3, 2025. The company, formerly known as Neothetics, Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This 8-K filing signals a significant development for Evofem Biosciences, Inc., potentially involving a new contract or partnership that could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the nature of this agreement is not detailed in the provided excerpt, necessitating further review.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- Neothetics, Inc. (company) — Former company name
- May 3, 2025 (date) — Date of earliest event reported
- May 8, 2025 (date) — Date of report
FAQ
What is the nature of the material definitive agreement entered into by Evofem Biosciences, Inc.?
The provided excerpt does not specify the details of the material definitive agreement, only that one was entered into on or before May 3, 2025.
When was the 8-K filing submitted?
The 8-K filing was submitted on May 8, 2025.
What was Evofem Biosciences, Inc. formerly known as?
Evofem Biosciences, Inc. was formerly known as Neothetics, Inc.
In which state is Evofem Biosciences, Inc. incorporated?
Evofem Biosciences, Inc. is incorporated in Delaware.
What is the principal executive office address for Evofem Biosciences, Inc.?
The principal executive office address is 7770 Regents Road, Suite 113-618, San Diego, California 92122.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding Evofem Biosciences, Inc. (EVFM).